INTRODUCTION {#s1}
============

Acute myocardial infarction (AMI) is one of the most serious cardiovascular diseases worldwide, as it is associated with high rates of morbidity and mortality. Multiple conventional risk factors and serum atherosclerotic biomarkers have been established for coronary artery disease (CAD) \[[@R1]\]. Advances in genomics and proteomics, especially gene-expression profiling using microarray have promoted the development of many novel molecular biomarkers with potential clinical values for AMI \[[@R2], [@R3]\]. Recently, long non-coding RNAs (lncRNAs) have attracted extensive interest in the field of cardiovascular diseases \[[@R4]\].

LncRNAs are a group of RNA transcripts with \> 200 nucleotides \[[@R5]\]. Although they lack protein coding capability, lncRNAs play an important role in many biological processes, including RNA-RNA interactions and epigenetic and post-transcription regulation \[[@R6]\]. It has been reported that lncRNAs play a role in regulating cardiac development and in the pathogenesis of heart failure \[[@R7]--[@R9]\]. For example, a lncRNA named cardiac hypertrophy related factor (CHRF) has been shown to regulate cardiac enlargement \[[@R10]\]. It is believed that lncRNAs also play a role in cardiovascular ageing \[[@R11]\]. Recently, Ounzain S et al \[[@R12]\] reported that expression levels of lncRNAs were altered in the cardiac tissue after AMI, which extended the pathophyiological role of lncRNA into AMI. The Uyghur is a Muslim minority in China, Uyghur population is count for 48.5% population in Xinjiang, the largest northwest province in China. The Uyghur has a unique lifestyle with a high incidence of CAD \[[@R13]\]. While expression of genome-scale lncRNAs and their potential biological functions in Uyghur AMI patients remain obscure.

Therefore, using microarray analysis, we investigated the expression of lncRNAs in peripheral blood cells of 5 Uyghur AMI patients and made comparison with matched healthy control subjects. The results were further validated by qRT-PCR in 50 Uyghur AMI patients and 50 Uyghur healthy controls. The differentially expressed lncRNAs were identified in the two groups and then integrated with mRNA expression data to predict the possible function of these lncRNAs.

RESULTS {#s2}
=======

Patients' enrollment and lncRNA categorization {#s2_1}
----------------------------------------------

This study recruited 55 AMI patients and 55 matched healthy controls. The clinical characteristics of study participants are shown in Table [1](#T1){ref-type="table"}. Peripheral blood samples were collected and total RNA was extraction. Expression profile of lncRNA and mRNA from 5 AMI patients and 5 matched healthy controls were detected using microarray, and the rest study participants were used for validation. In this study, we determined the expression of a total of 41,000 lncRNA probes. According to the categorization of lncRNAs by Clark et al in the GENCODE gene annotation \[[@R14]\], we classified all tested lncRNAs into 6 groups: sense, antisense, intronic, intergenic, bidirectional and unknown. The classification criteria were based on the lncRNA location with respect to protein-coding genes.

###### Clinical characteristics of study participants

                                   Healthy Control *n* = 55   AMI patient *n* = 55
  -------------------------------- -------------------------- ----------------------
  Age, years                       63.8 ± 9.3                 52.6 ± 10.9\*
  sex, male/female                 38/17                      29/26
  Heart rate, beats per minute     73.9 ± 9.0                 76.6 ± 10.4
  BMI (kg/m2)                      25.8 ± 3.2                 25.6 ± 3.6
  Systolic blood pressure, mmHg    129 ± 17                   126 ± 14
  Diastolic blood pressure, mmHg   76 ± 9                     80 ± 12
  Diabetes mellitus, %             13/42                      9/46
  Smoking,%                        28/27                      23/32
  Drinking, %                      20/35                      11/44\*
  Glucose, mmol/L                  4.9 ± 0.6                  7.5 ± 1.3\*
  TC, mmol/L                       1.8 ± 0.3                  4.2 ± 1.3\*
  TG, mmol/L                       1.9 ± 1.2                  2.5 ± 1.2\*
  HDL, mmol/L                      0.8 ± 0.1                  1.0 ± 0.1\*
  LDL, mmol/L                      3.0 ± 0.2                  3.5 ± 0.6\*

Data are mean value ± standard deviation. BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein. \**P \< 0.05* compared with healthy control.

Identification of distinct lncRNA expressions in AMI patients {#s2_2}
-------------------------------------------------------------

We first analyzed the locus-by-locus lncRNA probes from the peripheral blood of AMI patients (*n* = 5) and healthy controls (*n* = 5). By the criteria of a corrected *P* value \< 0.05 and an absolute fold change (FC) \> 2.0, we identified 3624 up-regulated and 1637 down-regulated lncRNAs that were significantly and differentially expressed between the two groups. The top 25 of distinctively expressed lncRNAs according to the FC values in Uyghur AMI patients are presented in Table [2](#T2){ref-type="table"}. As hierarchical clustering represents one of the simplest and most widely used clustering techniques for analysis of lncRNA and gene expression data which can then enable the generation of hypotheses about the relationships among samples \[[@R15]\], we adopted this technique in our experiment as well. The results of hierarchical clustering in these 10 samples (5 AMI patients and 5 healthy controls) showed distinguishable lncRNAs expression profiles (Figure [1A](#F1){ref-type="fig"}). The scatter and volcano plots are presented as visualizations used to assess lncRNA expression variation between the two groups (Figure [1B--1C](#F1){ref-type="fig"}). Every dot represents a lncRNA. The red dots represent the up-regulated lncRNAs (FC value \> 2, *P* \< 0.05), the green dots represent the down-regulated lncRNAs (FC value \< --2, *P* \< 0.05), the black dots represent the rest of lncRNAs (--2 \< FC value \< 2, *P* \> 0.05).

###### The top 25 of differentially expressed lncRNAs according to the fold change (FC) values in AMI patients of uyghur chinese compared with that in healthy controls

  lncRNA ID               Probe name   FC value   Regulation   class        database
  ----------------------- ------------ ---------- ------------ ------------ ---------------------
  **ENST00000541341.1**   p33400       18.66      down         Antisense    ENSEMBL
  **TCONS_00024652**      p33618       14.48      up           Antisense    HumanLincRNACatalog
  **ENST00000424119.1**   p9163        14.21      up           Intergenic   ENSEMBL
  **TCONS_00012852**      p23866       13.18      up           Intergenic   HumanLincRNACatalog
  **ENST00000365067.1**   p38671_v4    13.04      up           unkown       ENSEMBL
  **TCONS_00011823**      p23452       11.93      up           Divergent    HumanLincRNACatalog
  **ENST00000363358.1**   p38670_v4    11.76      up           unkown       ENSEMBL
  **ENST00000508732.2**   p5368        11.64      up           Intergenic   ENSEMBL
  **ENST00000561259.1**   p5097        11.50      up           Intergenic   ENSEMBL
  **TCONS_00004897**      p21231       11.30      up           Intergenic   HumanLincRNACatalog
  **uc031szk.1**          p44257_v4    11.05      up           unkown       UCSC
  **TCONS_00020349**      p18802       11.00      up           Intergenic   HumanLincRNACatalog
  **TCONS_00004284**      p20855       10.82      up           Intergenic   HumanLincRNACatalog
  **ENST00000565523.1**   p6372        9.41       up           Intergenic   ENSEMBL
  **uc002ywy.3**          p26170       9.22       up           Intronic     UCSC
  **ENST00000434741.1**   p11186       9.15       up           Intergenic   ENSEMBL
  **TCONS_00014223**      p23868       8.77       up           Intergenic   HumanLincRNACatalog
  **ENST00000566676.1**   p34425_v4    8.77       up           Intergenic   ENSEMBL
  **ENST00000518846.1**   p16012       8.76       up           Intergenic   ENSEMBL
  **ENST00000563515.1**   p6219        8.67       up           Intergenic   ENSEMBL
  **ENST00000597626.1**   p10862       8.56       up           Antisense    ENSEMBL
  **ENST00000424640.2**   p36969_v4    8.50       up           unkown       ENSEMBL
  **ENST00000365306.1**   p38669_v4    8.50       up           unkown       ENSEMBL
  **ENST00000447911.2**   p5449        8.27       up           Intergenic   ENSEMBL
  **TCONS_00004013**      p21307       8.22       up           Intergenic   HumanLincRNACatalog

![Differential expression of lncRNAs in patients with acute myocardial infarction (AMI) and control individuals in Uyghur of Chinese\
Hierarchical clustering analysis of 5261 lncRNAs that were differentially expressed in the two groups. (**A**) Expression values are represented in red and green, indicating expression above and below the median expression value in AMI patients (AMI-U1, AMI-U2, AMI-U3, AMI-U6, AMI-U8) or control individuals (N-U2, N-U3, N-U4, N-U5, N-U6), respectively. (**B**) Scatter plot of differential lncRNA expression. X-axis: N-U, Y-axis: AMI-U. (**C**) Volcano plot of differential lncRNA expression. X-axis: log2 fold change; Y-axis: −1 × log10 (corrected *p-value*) for each probes.](oncotarget-08-31449-g001){#F1}

Next, we analyzed distinctive lncRNAs based on their categorizations. Although many lncRNAs were not categorized (62.9%), among these classified lncRNAs, the greater proportions were intergenic (12.3%) and antisense (8.2%) versus that of bidirectional (4.9%), sense (5.6%) and intronic (5.0%) (Figure [2A](#F2){ref-type="fig"}). This pattern was also presented in Figure [2B--2C](#F2){ref-type="fig"} with regard to up- or down-regulated lncRNAs. The lengths of dysregulated lncRNAs were showed in Figure [3A](#F3){ref-type="fig"}. The chromosome distribution showed the number of up- and down-regulated lncRNAs located within each corresponding chromosome (Figure [3B](#F3){ref-type="fig"}).

![The classification of lncRNAs into six categories (sense, antisense, intronic, intergenic, bidirectional and unknown) according to their relationships with protein-coding genes\
(**A**) The numbers of identified lncRNAs in different categories. (**B**) Pie charts showing the number of up-regulated lncRNAs in each category. When a criteria of fold change \> 2 and *P* \< 0.05 was accepted, 3624 lncRNAs were up-regulated. (**C**) Pie charts showing the number of down-regulated lncRNAs in each category. When a criteria of fold change \> 2 and *P* \< 0.05 was accepted, 1637 lncRNAs were down-regulated.](oncotarget-08-31449-g002){#F2}

![The length and chromosomes distribution of dysregulated lncRNAs\
(**A**) The length distribution of dysregulated lncRNAs. (**B**) Distribution of up and down regulated lncRNAs location in different chromosomes.](oncotarget-08-31449-g003){#F3}

Identification of potentially functional lncRNAs in AMI {#s2_3}
-------------------------------------------------------

The function of most identified 5261 differentially expressed lncRNA probes remains unknown. In this experiment, we predicted their potential function via the annotation of their co-expressed mRNAs. First, expression profile of the genome-wide mRNA in these 5 AMI patients and 5 healthy controls were examined by microarray. Again, the criteria of a corrected *P* value \< 0.05 and an absolute FC \> 2 were used to identify significantly and differentially expressed mRNAs. Among the 34000 detected mRNA probes, a total of 3896 were found to be significantly and differentially expressed (Figure [4A](#F4){ref-type="fig"}). Of these mRNAs, 1833 were up-regulated and 2063 were down-regulated. The top 25 of distinctively expressed mRNAs according to the FC values in Uyghur AMI patients are presented in Table [3](#T3){ref-type="table"}. The scatter and volcano plots generated from these differentially expressed mRNAs are clearly segregated between the AMI and healthy control clusters (Figure [4B](#F4){ref-type="fig"}--[4C](#F4){ref-type="fig"}). Every dot represents a mRNA. The red dots indicate the up-regulated mRNAs (FC value \> 2, *P* \< 0.05), the green dots indicate the down-regulated mRNAs (FC value \< --2, *P* \< 0.05), the black dots indicate the rest of the mRNAs (--2 \< FC value \< 2, *P* \> 0.05). This result suggests that these mRNAs were substantially different between the AMI patients and healthy controls.

![Differential expression of mRNAs related to corresponding lncRNAs in patients with acute myocardial infarction (AMI) and control individuals in Uyghur ethnicity\
Hierarchical clustering analysis of 3896 mRNAs that were differentially expressed in the two groups. (**A**) Expression values are represented in red and green, indicating expression above and below the median expression value in AMI patients (AMI-U1, AMI-U2, AMI-U3, AMI-U6, AMI-U8) or control individuals (N-U2, N-U3, N-U4, N-U5, N-U6), respectively. (**B**) Scatter plot of differential mRNA expression. X-axis: N-U, Y-axis: AMI-U. (**C**) Volcano plot of differential mRNA expression. X-axis: log2 fold change; Y-axis: −1 × log10 (corrected *P*-value) for each probes.](oncotarget-08-31449-g004){#F4}

###### The top 25 of distinctively expressed mRNAs according to the fold change (FC) values in AMI patients of Uyghur Chinese compared with that in healthy controls

  Probe name          *P* value   FC value   Regulation   Gene Symbol    Ensembl ID
  ------------------- ----------- ---------- ------------ -------------- -----------------
  **A_23_P130689**    0.017       14.76      down         ELOF1          ENST00000590700
  **A_21_P0009030**   0.027       12.87      up           C16orf97       ENST00000562818
  **A_23_P407074**    0.042       11.90      down         DNM2           ENST00000408974
  **A_24_P14367**     0.003       11.50      down         PTBP1          ENST00000394601
  **A_24_P134235**    0.0183      10.37      down         KHSRP          ENST00000619396
  **A_24_P63019**     0.006       10.30      up           IL1R2          ENST00000457817
  **A_24_P276490**    0.010       10.01      down         LYPLA2         ENST00000420982
  **A_33_P3319967**   0.003       9.89       up           ARG1           ENST00000356962
  **A_23_P160902**    0.001       9.61       up           FCAMR          ENST00000324863
  **A_33_P3314500**   0.001       9.54       up           MUC6           ENST00000619759
  **A_21_P0000664**   0.009       9.02       down         CD4            ENST00000544344
  **A_33_P3589217**   0.019       8.91       down         SLC25A6        ENST00000484026
  **A_23_P118289**    0.018       8.86       down         BCL7C          ENST00000215115
  **A_23_P125771**    0.015       8.72       down         HCFC1          ENST00000310441
  **A_24_P400604**    0.003       8.65       up           RBMY1B         ENST00000623132
  **A_23_P404678**    0.024       8.61       down         RAB3D          ENST00000222120
  **A_33_P3262969**   0.001       8.48       up           COL4A6         ENST00000461897
  **A_23_P56213**     0.024       8.46       down         GRAMD1A        ENST00000600231
  **A_24_P224727**    0.037       8.30       down         CEBPA          ENST00000498907
  **A_21_P0003860**   0.007       8.24       up           LOC101928223   ENST00000504509
  **A_33_P3331952**   0.011       8.11       up           OR2M3          ENST00000456743
  **A_23_P29851**     0.010       8.10       down         LRPAP1         ENST00000515119
  **A_33_P3245575**   0.043       8.09       down         COLGALT1       ENST00000597075
  **A_23_P152024**    0.033       8.08       down         CSK            ENST00000564216
  **A_33_P3269539**   0.000       8.07       down         COL6A2         ENST00000397763

Among the Gene Ontology (GO) terms enriched up-regulated lncRNAs, the top 10 terms associated with biological processes in AMI patients included: (1) reproductive processes, (2) single-organism processes, (3) behavior, (4) hormone secretion, (5) biological adhesion, (6) metabolic processes, (7) cell killing, (8) developmental processes, (9) signaling and (10) multicellular organismal processes. The top 10 GO terms related to cellular components in AMI patients included: (1) membrane, (2) extracellular region, (3) virion, (4) macromolecular complex, (5) cell, (6) organelle, (7) collagen trimer, (8) extracellular region, (9) extracellular matrix and (10) nucleoid. The top 10 GO terms related to molecular function activity of AMI patients were the followings: (1) guanyl-nucleotide exchange factor, (2) nutrient reservoir, (3) translation regulator, (4) electron carrier, (5) catalytic, (6) binding, (7) antioxidant, (8) metallochaperone, (9) chemoattractant and (10) receptor regulator (Figure [5](#F5){ref-type="fig"}).

![GO analysis of differentially expressed lncRNAs which covers three domains: biological process, cellular component and molecular function\
X-axis: GO terms of biological process, cellular component and molecular function. The blue column indicates biological process, the green column indicates cellular component and the red column indicates molecular function. Y-axis on the left: percentage of genes (lncRNAs); Y-axis on the right: numbers of genes (lncRNAs).](oncotarget-08-31449-g005){#F5}

Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, the top 30 significant enriched pathway terms were acquired from 6 databases (KEGG PATHWAY, PID, BioCarta, Reactome, BioCyc and PANTHER). The most enriched pathways corresponding to the dysregulation of lncRNAs as related to AMI were apoptosis (8/30) and p53 pathway regulation (6/30) (Figure [6](#F6){ref-type="fig"}). The top 10 significant enriched disease terms include: (1) hypertension, (2) cardiac repolarization, (3) primary immunodeficiency, (4) breast cancer, (5) congenital disorders of DNA repair systems, (6) weight, (7) endometrial cancer, (8) immune system diseases, (9) asthma and (10) colorectal cancer (Figure [7](#F7){ref-type="fig"}). The top 30 terms involving these GO and KEGG pathways are presented in Figures [5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}.

![Pathway analysis of differentially expressed lncRNAs\
The top 30 significantly enriched pathways were calculated and plotted as the −1 × log10 (*P*-value). Pathway analysis is a functional analysis mapping genes to KEGG pathway and other pathway databases. Different colors represent different databases. The lower the *P*-value, the more significant the pathway.](oncotarget-08-31449-g006){#F6}

![Disease analysis of differentially expressed lncRNAs\
The top 30 significantly enriched disease terms were calculated and plotted as the −1 × log10 (*P*-value). The disease terms derived from five database: OMIM, KEGG disease, FunDO, GAD, NHGRI GWAS Catalog, which were indicated in blue, yellow, red, green, purple, respectively. The bar graph shows the top 30 enrichment score \[-log10 (*P*-value)\] value of the significantly enriched diseases.](oncotarget-08-31449-g007){#F7}

We then performed microarray analysis to investigate the corresponding gene changes of aberrantly expressed lncRNA for functional linking study. We found that the top 10 up- and 10 down-regulation lncRNAs were related to (1) inflammatory mediator regulation of Transient Receptor Potential (TRP) channels, (2) cardiac muscle contraction, (3) vascular smooth muscle contraction, (4) cytokine-cytokine receptor interaction, (5) platelet activation, (6) Malaria, (7) oxidative phosphorylation, (8) NF-kappa B signaling pathway, (9) JAK-STAT signaling pathway, (10) regulation of actin cytoskeleton, (11) cell cycle, (12) viral myocarditis, (13) TNF signaling pathway, (14) PPAR signaling pathway, (15) Toll-like receptor signaling pathway, (16) apoptosis, and (17) p53 signaling pathway (Figure [8](#F8){ref-type="fig"}).

![Kyoto encyclopedia of genes and genomes annotation for neighbor gene functions of predicated lncRNAs\
Hierarchical clustering analysis of 20 lncRNAs that were differentially expressed in the KEGG pathway terms. X-axis on the right (red): 10 higher expressed lncRNAs, X-axis on the left (green): 10 lower expressed lncRNAs. X-axis on the middle (black): no significantly expressed lncRNAs.](oncotarget-08-31449-g008){#F8}

LncRNA-mRNA network analysis {#s2_4}
----------------------------

To determine which lncRNAs and its corresponding mRNAs play critical roles in AMI progression, we constructed a correlated network of the differentially expressed lncRNAs and mRNAs. Correlations between lncRNAs and their corresponding genes (mRNAs) were performed with Pearson\'s correlation and coefficients obtained with no less than 0.99 were used to construct the network. As shown in Figures [9](#F9){ref-type="fig"}, [3](#F3){ref-type="fig"} source lncRNAs (p2355, p0898_imsncRNA716 and p0734_imsncRNA511 indicated by yellow cycles) were identified that were correlated with different expression (down-regulation or up-regulation) of corresponding genes indicated by green cycles. The size of cycles represented significant correlation, the red line represented positive correlation, and the blue line represented negative correlation. The details of the source lncRNA and their corresponding genes are presented in Table [4](#T4){ref-type="table"}. According to the correlated references and other studies, there were 8 corresponding genes related to inflammation, such as CD4, ITGB2, GSR, lnc-ZNHIT2-1, LOC100505564, lnc-ZNHIT2-1, SNRPB and MPG. And there were 10 corresponding genes related to apoptosis, such as CD4, ITGB2, GSR, lnc-ZNHIT2-1, LOC100505564, GLTP, GIT1, TNK2, TYK2 and MPG.

![LncRNA-mRNA-network was constructed based on the correlation analysis between the differentially expressed lncRNAs and mRNAs\
In the network, yellow node represents the lncRNAs, and green node represents the target mRNAs. The size of node is proportional to the outgoing link number. The red outgoing link represents up-regulation, the blue outgoing link represents down-regulation.](oncotarget-08-31449-g009){#F9}

###### LncRNA-mRNA network analysis

  LncRNA probe            Probe of target gene   Name of target gene   Correlation   *P* value
  ----------------------- ---------------------- --------------------- ------------- -----------
  **p2355**               A_33_P3219517          CD4                   0.999         5.33E-12
                          A_23_P89727            ITGB2                 0.995         2.48E-09
                          A_33_P3276784          CTDP1                 0.994         5.52E-09
                          A_33_P3332744          ARPC4                 0.994         5.64E-09
                          A_33_P3360684          ERGIC3                0.992         1.41E-08
                          A_33_P3387956          JADE2                 0.992         1.44E-08
                          A_33_P3410011          MAN1C1                0.992         1.74E-08
                          A_24_P216313           ATP1A4                0.992         2.06E-08
                          A_33_P3233070          GSR                   0.991         2.32E-08
                          A_24_P226278           lnc-ZNHIT2-1          0.991         2.36E-08
                          A_21_P0000664          LOC100505564          0.991         2.73E-08
                          A_24_P237778           GLTP                  0.991         2.79E-08
                          A_32_P31618            \-\--                 0.991         2.88E-08
                          A_33_P3835524          CYTH1                 0.991         2.97E-08
                          A_24_P307626           CORO1B                0.991         3.00E-08
                          A_33_P3401673          DPP7                  0.991         3.23E-08
                          A_33_P3266419          GIT1                  0.991         3.43E-08
                          A_23_P430411           PBXIP1                0.990         3.67E-08
                          A_24_P20383            POU2F2                0.990         3.88E-08
  **p0734_imsncRNA511**   A_23_P89727            CTDP1                 0.998         1.03E-10
                          A_33_P3219517          lnc-ZNHIT2-1          0.993         9.34E-09
                          p2355                  \-\--                 0.991         2.86E-08
                          A_33_P3276784          \-\--                 0.990         4.11E-08
                          A_23_P154675           SNRPB                 0.995         2.83E-09
                          A_23_P147439           ATXN2L                0.992         2.05E-08
                          A_33_P3219517          lnc-ZNHIT2-1          0.993         9.34E-09
                          A_32_P180741           TNK2                  0.995         3.33E-09
                          A_23_P165078           ABHD17A               0.991         3.41E-08
                          A_24_P289726           PSMD3                 0.992         2.15E-08
                          A_33_P3382303          FMNL1                 0.992         2.42E-08
  **p0898_imsncRNA716**   A_33_P3266419          GIT1                  --0.994       6.23E-09
                          A_33_P3387956          PBXIP1                --0.995       3.14E-09
                          p2355                  POU2F2                --0.995       3.02E-09
                          A_21_P0000664          CD4                   --0.995       2.99E-09
                          A_23_P141917           TYK2                  --0.992       2.24E-08
                          A_23_P119377           CYTH2                 --0.992       1.42E-08
                          A_24_P48162            MPG                   --0.990       3.87E-08
                          A_23_P59179            RXRB                  --0.991       3.12E-08
                          A_24_P216313           ERGIC3                --0.991       3.50E-08
                          A_24_P20383            ARPC4                 --0.993       9.50E-09
                          A_33_P3401673          GIT1                  --0.990       3.97E-08
                          A_24_P200942           TSC22D4               --0.990       3.87E-08
                          A_33_P3219517          lnc-ZNHIT2-1          --0.990       3.57E-08
                          A_24_P206343           MYO1G                 --0.992       1.92E-08
                          A_33_P3835524          POU2F2                --0.992       1.94E-08
                          A_33_P3410011          PBXIP1                --0.992       1.45E-08
                          A_21_P0000664          CD4                   --0.995       2.99E-09
                          A_32_P31618            GSR                   --0.992       2.08E-08

qRT-PCR validation {#s2_5}
------------------

To validate the microarray data of lncRNA expression, we assessed the expression level of three randomly selected lncRNAs using qRT-PCR from peripheral blood samples of Uyghur AMI patients (*n* = 50) and healthy controls (*n* = 50). A description of the three down-regulated lncRNAs are presented in Table [5](#T5){ref-type="table"}, and the PCR primers of these three lncRNAs are presented in Table [6](#T6){ref-type="table"}. As shown in Figure [10](#F10){ref-type="fig"}, differences in the expression of three lncRNAs were detected in Uyghur AMI patients compared with healthy controls: lncRNA TCONS_00025701 was the most significantly decreased (8.16-fold), followed by lncRNA ENST00000421157.1 (5.29-fold), and lncRNA ENST00000416860.2 (1.52-fold), respectively. These results were consistent with the findings obtained from the microarray chip analysis.

###### The randomly selected lncRNAs

  lncRNA ID               *P* value   Fold change   Regulation   Probe    Chromosome   Start       End         Class
  ----------------------- ----------- ------------- ------------ -------- ------------ ----------- ----------- ------------
  **ENST00000416860.2**   0.013       2.69          down         p36      1            2481358     2488450     Antisense
  **ENST00000421157.1**   0.005       3.05          down         p351     1            113554308   113615727   Divergent
  **TCONS_00025701**      0.030       5.80          down         p20189   17           55122437    55128557    Intergenic

###### The PCR primers of the randomly selected lncRNAs

  Gene name               Forward primer          Reverse primer            Hybridization temperature (°c)
  ----------------------- ----------------------- ------------------------- --------------------------------
  **ENST00000416860.2**   TTTTCGGAGGCAGGTTCCAG    CACCTCGCATGTGCGTTTAT      60
  **ENST00000421157.1**   TGGCACTGGGCACTTGATAA    CAAGTGTGCAGTAGGTATTAGCC   60
  **TCONS_00025701**      GAGGAGCAGTTCATCCCAGTC   GCAACCACCTGTTCCACGA       60

![qRT-PCR validation of 3 randomly selected lncRNAs in study participants\
Compared to healthy controls, expression (log2 fold change) of 3 lncRNAs, ENST00000416860.2, ENST00000421157.1 and TCONS_00025701 was significantly lower in patients with acute myocardial infarction (AMI), results were consistent with the findings obtained from the microarray chip analysis. *P* \< 0.05 vs. controls.](oncotarget-08-31449-g010){#F10}

DISCUSSION {#s3}
==========

AMI, the most common heart diseases, is a major cause of death and disability worldwide and exerts huge burdens on the society \[[@R16]\]. Identification of novel biological information or biomarkers which may have a potential in better stratification and management of patients with acute coronary artery syndrome. LncRNAs had long been considered as simply transcriptional noise \[[@R17]\]. However, recent studies have showed that lncRNAs play important roles in pathophysiology of cardiovascular diseases involving in regulations of basal transcription, post-transcriptional processes, DNA methylation, epigenetic modifications, histone modification, directly bind proteins and protein function \[[@R18]--[@R21]\]. LncRNAs are now emerging as a novel class of gene regulators to cardiovascular diseases \[[@R22]\].

Following the exploration in expression pattern of lncRNAs in some types of cardiovascular disease including AMI in other populations, we investigated the genome-wide expression profile of lncRNAs in Uyghur ethnicity in China. Using microarray, expression profiles of lncRNA and mRNA in 5 Uyghur AMI patients and 5 Uyghur healthy volunteers were studied. A total 3624 up- and 1637 down-regulated lncRNA probes were identified to be significantly and differentially expressed in AMI patients and accordingly in mRNA levels, 1833 mRNAs were up-regulated and 2063 mRNAs were down-regulated when compared with that in healthy controls. There are several studies investigated the relationship between lncRNAs and AMI. Ounzain S *et al*. found that there were 988 (67 up-regulated and 66 down-regulated) UCSC-annotated lncRNAs and 1521 (86 up-regulated and 225 down-regulated) novel unannotated lncRNAs in AMI patients \[[@R12]\]. Liu Y *et al*. studied expression profile and ontology analysis of lncRNAs in post-ischemic heart, they found that 64 lncRNAs were up-regulated and 87 down-regulated, accordingly, they also revealed 50 mRNAs were up-regulated and 60 down-regulated in the ischemia-reperfused murine myocardium \[[@R23]\].

Further, in our study, the potential function of lncRNAs and their co-expressed mRNAs were predicted. The most enriched pathways corresponding to the dysregulation of lncRNAs in related to AMI were apoptosis and its corresponding p53 signaling pathway. Other dysregulated lncRNAs were related to inflammatory signaling pathway and contraction of cardiac muscle and vascular smooth muscle. These information suggest that there might be coordinated patterns between lncRNAs and its co-expressed mRNAs involved in the development of AMI. Furthermore, we analyzed the relation between altered lncRNAs and the network of inflammation- and apoptosis-related mRNAs. We found that the lncRNAs (p2355, p0898_imsncRNA716, p0734_imsncRNA511) and their co-expressed mRNAs, such as CD4, ITGB2, GSR, lnc-ZNHIT2-1, LOC100505564, lnc-ZNHIT2-1, SNRPB and MPG were related to inflammation. These lncRNAs and their co-expressed mRNAs, such as CD4, ITGB2, GSR, lnc-ZNHIT2-1, LOC100505564, GLTP, GIT1, TNK2, TYK2 and MPG, related to the apoptosis. We speculated that these lncRNAs and their co-expressed mRNAs may participate in AMI occurrence and development. However, this hypothesis needs to be further investigated.

Some lncRNAs have been reported to be potential biomarkers in cardiovascular disease. The mitochondrial lncRNA uc022bqs.1 (LIPCAR) was downregulated early after AMI but upregulated during later stages which identified patients developing cardiac remodeling and were independently to other risk markers associated with future cardiovascular deaths \[[@R24]\]. Increased expression of MIAT \[[@R25]\] and circulating lncRNA OTTHUMT00000387022 in monocytes \[[@R26]\] have been reported to link with a high risk of CAD. LncRNA, ANRIL expression is associated with the chromosome 9p21 genotype and correlated with atherosclerosis severity \[[@R27]\] and further ANRIL may also increase the risk of ischemic stroke through regulation of the CARD8 pathway \[[@R28]\]. The lncRNA MIAT has been reported as a biomarkers for severe LV remodeling after AMI \[[@R29]\], and the circulating levels of lncRNAs, such as ANRIL \[[@R30]\] and lncRNA-P21 \[[@R31]\] were also increased in atherosclerosis which may be important in its pathogenesis. Compared to these reports, we found in our study that lncRNA, MIAT, was decreased in Uyghur AMI patients versus healthy controls (FC value was 3.11, *P* = 0.006), and other lncRNAs such as ANRIL, LIPCAR, lncRNA-P21 and OTTHUMT00000387022 were not detected. However, we found that the expression levels of lncRNA ENST00000416860.2, ENST00000421157.1 and TCONS_00025701 were decreased in AMI patients, which identified previously non-reported novel lncRNAs with altered expression in the setting of AMI. Our results provide a supplementary data in this field.

We have to admit the limitation of this study, as the participants in this study were from a single center and only tested in one ethnic group, whether there is a difference in patients from different areas and races that is unknown. Therefore, its validity should be tested further in a large population.

In conclusion, the present study using microarray approach to examine the expression profile of lncRNA in peripheral blood from Uyghur AMI patients in comparison with matched healthy controls. Results provide previously unreported bioinformation on genomic-wide lncRNA expression and corresponding mRNA expression in Uyghur AMI patients. Potential functional link in post-MI revealed dysregulated lncRNA expression involving a variety of biological and pathological processes. Notably, top 20 aberrantly expressed lncRNA were related to various aspects of inflammatory regulation and apoptosis. These findings provide useful bioinformation with functional links, which may have a potential role in the development of AMI.

MATERIALS AND METHODS {#s4}
=====================

Patients and sample collection {#s4_1}
------------------------------

This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University and was conducted according to the standards of the Declaration of Helsinki. Written informed consent was obtained from all the participants. Patients with AMI treated with primary percutaneous coronary intervention were recruited in this study. AMI patients was defined by the following: (a) occluded major coronary artery: TIMI (thrombolysis in MI), 0 flow in the left anterior descending, circumflex, or right coronary artery; (b) peak creatine kinase (CK) activity \>600 U/L (3 times higher than the upper limit of the reference interval). (c) positive troponin T (TnT) concentration \>0.15 μg/L. Exclusion criteria included the following: (a) acute coronary syndrome, heart failure and severe valvular heart disease, (b) infectious processes in last 4 weeks or active chronic inflammatory disease, (c) other severe systemic diseases (such as renal failure and hepatic disease), malignant tumor, and autoimmune diseases or patients who took anti-inflammatory drugs, (d) other inflammatory diseases. Blood samples were collected between December 2014 and September 2015 at the First Affiliated Hospital of Xinjiang Medical University. Five AMI patients and 5 healthy volunteers were randomly selected using coding system (AMI-U1, AMI-U2, AMI-U3, AMI-U6, AMI-U8) and (Normal N-U2, N-U3, N-U4, N-U5, N-U6) for lncRNA chip analysis. In addition, blood samples from the rest of 50 AMI patients and 50 healthy volunteers were obtained to validate the lncRNA expression level using qRT-PCR.

RNA extraction, labeling and hybridization {#s4_2}
------------------------------------------

Total RNA was extracted from peripheral blood cells using the Trizol reagent (Invitrogen) and purified with mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) according to manufacter\'s protocol. The purity and concentration of RNA were determined from OD260/280 readings using spectrophotometer (NanoDrop ND-1000). RNA integrity was determined by 1% formaldehyde denaturing gel electrophoresis. Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). cDNA labeled with a fluorescent dye (Cy5 and Cy3-dCTP) was produced by Eberwine\'s linear RNA amplification method and subsequent enzymatic reaction \[[@R32]\]. Double-stranded cDNAs (containing the T7 RNA polymerase promoter sequence) were synthesized from 1ug total RNA using the CbcScript reverse transcriptase with cDNA synthesis system according to the manufacturer\'s protocol (Capitalbio) with the T7 Oligo (dT) and T7 Oligo (dN) \[[@R33]\]. After completion of double-stranded cDNA (dsDNA) synthesis using DNA polymerase and RNase H, the dsDNA products were purified using a PCR NucleoSpin Extract II Kit (MN) and eluted with 30 μL elution buffer. The eluted double-stranded cDNA products were vacuum evaporated to 16 μL and subjected to 40 μL *in vitro* transcription reactions at 37°C for 14 h using a T7 Enzyme Mix. The amplified cRNA was purified using the RNA Clean-up Kit (MN).

Klenow enzyme labeling strategy was adopted after reverse transcription using CbcScript II reverse transcriptase \[[@R34]\]. Briefly, 2 μg amplified RNA was mixed with 4 μg random nanomer, denatured at 65°C for 5 min, and cooled on ice. Then, 5 μL of 4×first-strand buffer, 2 μL of 0.1M DTT, and 1.5 μL CbcScript II reverse transcriptase were added. The mixtures were incubated at 25°C for 10 min, then at 37°C for 90 min. The cDNA products were purified using a PCR NucleoSpin Extract II Kit (MN) and vacuum evaporated to 14 μL. The cDNA was mixed with 4 μg random nanomer, heated to 95°C for 3 min, and snap cooled on ice for 5 min. Then, 5 μL Klenow buffer, dNTP, and Cy5-dCTP or Cy3-dCTP (GE Healthcare) were added to final concentrations of 240 μM dATP, 240 μM dGTP, 240 μM dTTP, 120 μM dCTP, and 40 μM Cy-dCTP. Klenow enzyme (1.2 μL) was then added, and the reaction was performed at 37°C for 90 min. Labeled cDNA was purified with a PCR NucleoSpin Extract II Kit (MN) and resuspended in elution buffer.

Labeled controls and test samples labeled with Cy5-dCTP and Cy3-dCTP were dissolved in 80 μL hybridization solution containing 3×SSC, 0.2% SDS, 5×Denhardt\'s solution and 25% formamide. DNA in hybridization solution was denatured at 95°C for 3 min prior to loading onto a microarray. Arrays were hybridized in a Agilent Hybridization Oven overnight at a rotation speed of 20 rpm and a temperature of 42°C, and then washed with two consecutive solutions (0.2% SDS, 2× SSC at 42°C for 5 min, and 0.2× SSC for 5 min at room temperature).

LncRNA and mRNA microarrays {#s4_3}
---------------------------

Approximately 200 ng of total RNA from each sample was used for the lncRNA microarray analysis. LncRNA expression was analyzed using Agilent human lncRNA + mRNA Array V4.0 (4 × 180 K format), with each array containing probes interrogating about 41,000 human lncRNAs and about 34,000 human mRNAs (Agilent, USA). Those lncRNA and mRNA target sequences were merged from multiple databases, 23898 from GENCODE/ENSEMBL, 21488 from LNCipedia, 14353 from Human LincRNA Catalog \[[@R35]\], 13701 from NRED (ncRNA Expression Database), 7760 from RefSeq, 5627 from USCS, 3019 from LncRNAs-a (Enhancer-like), 1053 from Antisense ncRNA pipeline, 1038 from H-InvDB, 962 UCRs, 848 from Chen Ruisheng lab (Institute of Biophysics, Chinese Academy of Science) and 407 Hox ncRNAs. Each RNA was detected by probes that were replicated 2 times. The array also contained 4974 control probes (Agilent, USA).

Microarray imaging and data analysis {#s4_4}
------------------------------------

The lncRNA and mRNA array data were analyzed for data summarization, normalization and quality control with use of GeneSpring software V13.0 (Agilent). Differentially expressed lncRNAs with statistical significance were identified through Volcano Plot filtering and hierarchical clustering. Differentially expressed genes were identified through the random variance model and *p* values were calculated using the paired *t*-test. The significance thresholds established for the up- and down-regulated genes required a fold change (FC) ≥ 2.0 and a *P* ≤ 0.05. The data was Log 2 transformed and median centered by genes using the Adjust Data function of CLUSTER 3.0 software. Data were then further analyzed using hierarchical clustering with average linkage. Finally, tree visualization was performed with use of Java Treeview (Stanford University School of Medicine, Stanford, CA, USA).

LncRNA related functional and pathway analyses {#s4_5}
----------------------------------------------

GO analysis is a functional analysis for relating differentially expressed mRNAs with GO categories. The GO categories were derived from the Gene Ontology Consortium ([www.geneontology.org](http://www.geneontology.org)), which describes gene product attributes within three defined terms: biological processes, molecular functions and cellular components. The *P*-value denotes the significance of the GO term enrichment. The lower the *P*-value, the more significant the GO term (a *P* \< 0.05 is recommended).

Pathway analysis is a functional analysis that maps genes to the Kyoto Encyclopedia of Genes and Genome (KEGG) pathways. It was used to determine the main pathway of the differentially expressed genes according to KEGG. Fisher\'s exact test and χ^2^ tests were used to select the main pathway, and the significance threshold was defined by *p* value and false discovery rate (FDR) \[[@R36]\]. The lower the *p*-value, the more significant the pathway (the *P*-value cut-off is 0.05).

Construction of the coding-non-coding gene co-expression network {#s4_6}
----------------------------------------------------------------

The coding-non-coding gene co-expression network (CNC network) was constructed based on correlation analysis between the differential expressed lncRNAs and mRNAs. For each pair of genes, a Pearson correlation coefficient was calculated and the significant correlation pairs were selected for construction of the network. LncRNAs and mRNAs with Pearson correlation coefficients not less than 0.99 were selected to draw the network though the open source bioinformatics software Cytoscape. In a network analysis, a degree centrality is defined as the link numbers between nodes. A degree is the simplest and most important measure of a gene centrality within a network that determines its relative importance \[[@R37]\].

qRT-PCR {#s4_7}
-------

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate the lncRNA expression level. In brief, the total RNA was isolated using Trizol reagent (Invitrogen) and then reverse transcribed to cDNA using RNeasy Mini Kit (QIAGEN, China) in accordance to the manufacturer\'s protocol. Primers of each lncRNA were designed using Primer 5.0 and checked with the Basic Local Alignment Search Tool (BLAST) from NCBI to confirm that the amplified product was unique. The primer sequences used are shown in Table [6](#T6){ref-type="table"}. Real-time PCR was performed using Power SYBR Green PCR Master (Applied Biosystems, USA) in 7900 HT Fast RealTime PCR system (Applied Biosystems, USA). The threshold cycle value (Ct) of each product was determined and Expression levels were calculated using the method of 2^−ΔΔct^ and normalized to the internal control of GAPDH. The level of each lncRNA in MI patients was expressed as the fold changes against the averaged level of the same lncRNA in healthy controls.

Statistical analysis {#s4_8}
--------------------

The data were analyzed with IBM SPSS Statistics 18.0 software (SPSS Inc, Chicago, ILLinois, USA). Differential expression levels of lncRNAs were compared via independent-sample *t*-tests between two groups. GO and pathway analyses were evaluated using Fisher\'s exact test. All values are expressed as the mean ± standard deviation, and significance was assigned at the *P \< 0.05* level.
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